Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14821483148414851486148714881489149014911492...15771578»
  • ||||||||||  Review, Journal:  Evaluation and Management of Cardiac Tumors. (Pubmed Central) -  Mar 23, 2018   
    Primary and secondary cardiac tumors have particular characteristics in echocardiography and CMR. Imaging of cardiac tumors plays an important role in establishing a diagnosis and in planning management.
  • ||||||||||  Clinical, Journal:  Detection of circulating tumor DNA in patients with osteosarcoma. (Pubmed Central) -  Mar 22, 2018   
    To determine whether somatic alterations can be detected in ctDNA and perhaps applied to patient management in this disease, we collected germline, tumor, and serial plasma samples from pediatric, adolescent, and young adult patients with osteosarcoma and used targeted Next Generation Sequencing (NGS) to identify somatic single nucleotide variants (SNV), insertions and deletions (INDELS), and structural variants (SV) in 7 genes commonly mutated in osteosarcoma. We demonstrate that patient-specific somatic alterations identified through comparison of tumor-germline pairs can be detected and quantified in cell-free DNA of osteosarcoma patients.
  • ||||||||||  pomalidomide / Generic mfg.
    Enrollment closed, Enrollment change:  Pomalidomide for Kaposi Sarcoma in People With or Without HIV (clinicaltrials.gov) -  Mar 22, 2018   
    P1/2,  N=28, Active, not recruiting, 
    Trial completion date: Jun 2020 --> Jan 2021 Recruiting --> Active, not recruiting | N=40 --> 28
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Trial completion date, Trial primary completion date, Metastases:  TVEC and Preop Radiation for Sarcoma (4 ml Dose) (clinicaltrials.gov) -  Mar 22, 2018   
    P1/2,  N=32, Recruiting, 
    Trial completion date: Oct 2019 --> Oct 2020 Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Apr 2018 --> Apr 2020
  • ||||||||||  Trial completion date, Trial primary completion date:  MMS-TM: Validation of MMS Test for Cancer Monitoring (clinicaltrials.gov) -  Mar 21, 2018   
    P=N/A,  N=100, Recruiting, 
    These studies demonstrate that stress-dependent plasticity of CXCR4 is, in part, mediated by epigenetic plasticity and a bivalent promoter. Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  azathioprine / Generic mfg.
    Journal:  Follicular dendritic sarcoma masquerading as fibrosing mediastinitis. (Pubmed Central) -  Mar 21, 2018   
    Repeat biopsy was consistent with primary mediastinal follicular dendritic cell sarcoma. The manuscript highlights the heightened need for suspecting occult malignancies in cases of FM presenting with an indeterminate cause.
  • ||||||||||  Seprehvir (HSV1716) / Sorrento
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) -  Mar 21, 2018   
    P1,  N=18, Completed, 
    The manuscript highlights the heightened need for suspecting occult malignancies in cases of FM presenting with an indeterminate cause. Recruiting --> Completed | N=30 --> 18 | Trial completion date: Jul 2018 --> Mar 2018 | Trial primary completion date: Jul 2018 --> Mar 2018
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial completion date, Trial primary completion date:  Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Mar 20, 2018   
    P2,  N=53, Active, not recruiting, 
    Recruiting --> Completed | N=30 --> 18 | Trial completion date: Jul 2018 --> Mar 2018 | Trial primary completion date: Jul 2018 --> Mar 2018 Trial completion date: Jul 2019 --> Jul 2018 | Trial primary completion date: Jul 2019 --> Jul 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma. (Pubmed Central) -  Mar 17, 2018   
    We describe a patient with recurrent GBM who had disease progression following standard surgical treatment and concomitant chemoradiotherapy, and was found to have sarcomatous transformation after initiation of TTF therapy with bevacizumab...The possibility of a causal connection between TTF therapy and sarcomatous transformation needs to be further evaluated. No such case of apparent sarcoma formation in the CNS following chemoradiotherapy and/or TTF treatment for GBM has been reported.
  • ||||||||||  imatinib / Generic mfg.
    Journal:  Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. (Pubmed Central) -  Mar 15, 2018   
    The main and best-established mechanism of resistance is the polyclonal expansion of multiple subpopulations harboring different secondary KIT mutations. The present review aims at summarizing current and forthcoming treatment directions in advanced imatinib-resistant GIST supported by a strong biological rationale.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment open:  Pembrolizumab in Neoplasms or Lymphomas (clinicaltrials.gov) -  Mar 13, 2018   
    P2,  N=30, Recruiting, 
    Trial completion date: Dec 2020 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Mar 12, 2018   
    P2,  N=70, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jun 2018 --> Jun 2019
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Journal:  Evolving Treatment of Soft Tissue Sarcoma. (Pubmed Central) -  Mar 11, 2018   
    For unresectable or metastatic disease, doxorubicin remains the backbone of chemotherapy, but other agents have improved on its single-agent efficacy. Chief among them is olaratumab, which, in combination with doxorubicin, is preferred over doxorubicin alone in the updated NCCN Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma.
  • ||||||||||  Journal, BRCA Biomarker:  Mutational landscape of radiation-associated angiosarcoma of the breast. (Pubmed Central) -  Mar 10, 2018   
    These data demonstrate a mutational pattern associated with genes involved in DNA repair. While important in revealing the biology behind these tumors, it may also suggest new treatment strategies that will prove successful.
  • ||||||||||  Votrient (pazopanib) / Novartis
    Journal:  Pazopanib radio-sensitization of human sarcoma tumors. (Pubmed Central) -  Mar 8, 2018   
    Pre-treatment with a single dose of Pazopanib increased SDRT-induced ASMase activity and endothelial dysfunctionand, enhancing SDRT tumor cure, and exhibiting critical dependence on timing relative to SDRT exposure, suggesting a mechanism of action identical to that demonstrated for anti-VEGF/VEGFR2 antibodies. These results demonstrate the ability of Pazopanib to shift the response towards tumor cure and could therefore have a significant impact on clinical trial development in combination with SDRT for sarcoma cancer patients.
  • ||||||||||  mebendazole / Generic mfg.
    Trial initiation date, Trial primary completion date:  A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas (clinicaltrials.gov) -  Mar 8, 2018   
    P1/2,  N=36, Recruiting, 
    Active, not recruiting --> Completed | N=50 --> 10 Initiation date: Apr 2015 --> Oct 2013 | Trial primary completion date: Apr 2018 --> Apr 2020
  • ||||||||||  mecbotamab vedotin (BA3011) / BioAtla
    Enrollment open, Trial initiation date, Combination therapy, Metastases:  BA3011-001: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma (clinicaltrials.gov) -  Mar 8, 2018   
    P1/2,  N=120, Recruiting, 
    Trial completion date: Dec 2021 --> Feb 2022 | Initiation date: Dec 2017 --> Apr 2018 | Trial primary completion date: Dec 2019 --> Feb 2020 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
  • ||||||||||  New trial:  Pediatric PET/MR Image Registry (clinicaltrials.gov) -  Mar 8, 2018   
    P=N/A,  N=100, Recruiting, 
  • ||||||||||  Enrollment open, Trial initiation date:  ETOILE: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (clinicaltrials.gov) -  Mar 7, 2018   
    P=N/A,  N=250, Recruiting, 
    These findings not only inform communication practices with AYAs but also suggest opportunities for interventions to potentially improve outcomes. Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> Dec 2017
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Enrollment closed, Combination therapy, Monotherapy:  A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) -  Mar 7, 2018   
    P1b,  N=40, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> Dec 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Preclinical, Journal:  Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. (Pubmed Central) -  Mar 7, 2018   
    Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR-34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination...In addition, triple-drug therapy improved the overall survival to the greatest extent in experimental metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and protein molecules as a novel therapeutic strategy for the treatment of metastasis.
  • ||||||||||  paclitaxel / Generic mfg.
    Journal:  Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. (Pubmed Central) -  Mar 7, 2018   
    We found that the expression of PD-L1 could be efficiently disrupted by CRISPR/Cas9 system and PD-L1 knockdown increased drug sensitivities for doxorubicin and paclitaxel. These results suggest that PD-L1 is an independent prognostic factor in osteosarcoma and that PD-L1 knockout by CRISPR/Cas9 may be a therapeutic approach for the treatment of osteosarcoma.